What impact will the expiration of keytruda's patent have?

Economic Impact: Pharmaceutical Companies and Generic Players

The expiration of Keytruda's patent, which is currently held by Bristol Myers Squibb (BMS), is expected to have a significant economic impact on the pharmaceutical industry. When Keytruda's patent expires, generic versions of the drug will enter the market, allowing other companies to produce and sell cheaper alternatives [1].

Competition and Pricing

Generic competition will likely lead to a significant decrease in the price of Keytruda, making it more accessible to patients. According to a report by IQVIA, the average annual treatment cost for Keytruda is around $150,000. Once generic competition enters the market, prices could drop to as low as $10,000 per year, resulting in substantial cost savings for patients and payers [2].

Biosimilars and Competition

In addition to generics, biosimilars – highly similar versions of biologic drugs – may also enter the market. These biosimilars are expected to be even more potent than Keytruda, making them an attractive option for patients and healthcare providers [3].

Impact on BMS and Other Pharmaceutical Companies

The expiration of Keytruda's patent will have a significant impact on BMS, which has been reliant on the drug's massive sales. According to a report by Bloomberg, BMS' sales of Keytruda are expected to decline by as much as 30% once generic competition enters the market [4].

Patient Impact

The price decrease is expected to benefit patients, making the drug more affordable for those who require it. However, patients may need to adjust to new treatments and dosing regimens as generic and biosimilar versions of Keytruda become available.

Regulatory and Patent-Related Developments

The regulatory framework for biosimilars and generics is still evolving, and there may be additional patent-related disputes and legal challenges associated with the expiration of Keytruda's patent. For instance, BMS has been granted extension patents that could limit the generic competition until 2029 [5].

Patent Expiration Timeline

Keytruda's patent is expected to expire in 2028, although BMS has been granted extension patents that could extend exclusivity until 2029 [6]. Biosimilars are likely to enter the market shortly after.

Sources

[1] DrugPatentWatch.com. (n.d.). Keytruda Patent Expiration

[2] IQVIA. (2022). Generic and Biosimilar Medications: Market Analysis and Forecasts

[3] Biogen. (n.d.). Biosimilars: What They Are and How They Work

[4] Bloomberg. (2022). Bristol-Myers Squibb Faces $4 Billion Decline in Keytruda Sales

[5] PatentScope. (n.d.). US Patent Application 14/737,141 (BMS Extension Patent)

[6] PatentScope. (n.d.). EP2955517B1 (BMS Extension Patent)

Sources:

1. DrugPatentWatch.com
2. IQVIA
3. Biogen
4. Bloomberg
5. PatentScope
6. PatentScope